249 related articles for article (PubMed ID: 18668536)
1. Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease.
Distler JH; Manger B; Spriewald BM; Schett G; Distler O
Arthritis Rheum; 2008 Aug; 58(8):2538-42. PubMed ID: 18668536
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate treatment of nephrogenic systemic fibrosis.
Kay J; High WA
Arthritis Rheum; 2008 Aug; 58(8):2543-8. PubMed ID: 18668587
[TBL] [Abstract][Full Text] [Related]
4. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results.
Daniels CE; Lasky JA; Limper AH; Mieras K; Gabor E; Schroeder DR;
Am J Respir Crit Care Med; 2010 Mar; 181(6):604-10. PubMed ID: 20007927
[TBL] [Abstract][Full Text] [Related]
5. Is imatinib mesylate a promising drug in systemic sclerosis?
van Daele PL; Dik WA; Thio HB; van Hal PT; van Laar JA; Hooijkaas H; van Hagen PM
Arthritis Rheum; 2008 Aug; 58(8):2549-52. PubMed ID: 18668570
[TBL] [Abstract][Full Text] [Related]
6. Use of imatinib mesylate in gastrointestinal stromal tumours: Pan-Birmingham Cancer Network experience.
Wong DW; Lupton SC; Bhatt L; Gross L; Tanière P; Peake DR; Spooner D; Geh JI
Clin Oncol (R Coll Radiol); 2008 Sep; 20(7):517-22. PubMed ID: 18514495
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate for the treatment of hypereosinophilic syndromes.
Antoniu SA
Curr Opin Investig Drugs; 2006 Nov; 7(11):980-4. PubMed ID: 17117585
[TBL] [Abstract][Full Text] [Related]
8. Imatinib as a novel therapeutic approach for fibrotic disorders.
Distler JH; Distler O
Rheumatology (Oxford); 2009 Jan; 48(1):2-4. PubMed ID: 19029132
[No Abstract] [Full Text] [Related]
9. Acute renal failure secondary to imatinib mesylate treatment in prostate cancer.
Foringer JR; Verani RR; Tjia VM; Finkel KW; Samuels JA; Guntupalli JS
Ann Pharmacother; 2005 Dec; 39(12):2136-8. PubMed ID: 16288076
[TBL] [Abstract][Full Text] [Related]
10. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial.
Prey S; Ezzedine K; Doussau A; Grandoulier AS; Barcat D; Chatelus E; Diot E; Durant C; Hachulla E; de Korwin-Krokowski JD; Kostrzewa E; Quemeneur T; Paul C; Schaeverbeke T; Seneschal J; Solanilla A; Sparsa A; Bouchet S; Lepreux S; Mahon FX; Chene G; Taïeb A
Br J Dermatol; 2012 Nov; 167(5):1138-44. PubMed ID: 23039171
[TBL] [Abstract][Full Text] [Related]
11. Paraneoplastic insulin resistance syndrome in advanced aggressive fibromatosis (desmoid tumor) treated by imatinib mesylate.
Folli F; Galimberti G; Pastore M; Davalli AM; Bosi E
Diabetes Care; 2006 Sep; 29(9):2178-80. PubMed ID: 16936177
[No Abstract] [Full Text] [Related]
12. Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma.
Porta C; Mutti L; Tassi G
Cancer Chemother Pharmacol; 2007 Jan; 59(1):149-50. PubMed ID: 16636799
[No Abstract] [Full Text] [Related]
13. Maintained efficacy of the tyrosine kinase inhibitor imatinib mesylate in a patient with rheumatoid arthritis.
Eklund KK; Lindstedt K; Sandler C; Kovanen PT; Laasonen L; Juurikivi A; Wolff H; Mykkänen M; Joensuu H
J Clin Rheumatol; 2008 Oct; 14(5):294-6. PubMed ID: 18824923
[No Abstract] [Full Text] [Related]
14. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
Cohen MH; Farrell A; Justice R; Pazdur R
Oncologist; 2009 Feb; 14(2):174-80. PubMed ID: 19193781
[TBL] [Abstract][Full Text] [Related]
15. Treatment of polycythemia vera with recombinant interferon alpha (rIFNalpha) or imatinib mesylate.
Silver RT
Curr Hematol Rep; 2005 May; 4(3):235-7. PubMed ID: 15865878
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate for the treatment of pulmonary arterial hypertension.
ten Freyhaus H; Dumitrescu D; Berghausen E; Vantler M; Caglayan E; Rosenkranz S
Expert Opin Investig Drugs; 2012 Jan; 21(1):119-34. PubMed ID: 22074410
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies.
Distler JH; Distler O
Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i48-51. PubMed ID: 19995744
[TBL] [Abstract][Full Text] [Related]
18. Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?
Beyer C; Distler JH; Distler O
Swiss Med Wkly; 2010; 140():w13050. PubMed ID: 20419513
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases.
Jais X; Launay D; Yaici A; Le Pavec J; Tchérakian C; Sitbon O; Simonneau G; Humbert M
Arthritis Rheum; 2008 Feb; 58(2):521-31. PubMed ID: 18240255
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate ameliorates the dystrophic phenotype in exercised mdx mice.
Bizario JC; Cerri DG; Rodrigues LC; Oliveira GL; Nomizo A; de Araujo DD; Fukuhara PS; Ribeiro JC; de Castro FA; Costa MC
J Neuroimmunol; 2009 Jul; 212(1-2):93-101. PubMed ID: 19508953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
